ELICIO THERAPEUTICS INC (ELTX)
Health Care · Cancer immunotherapy · NASDAQ
Elicio develops lymph node-targeted "off-the-shelf" cancer immunotherapies using proprietary AMP technology to generate robust T cell responses against common KRAS mutations in pancreatic, colorectal, and other solid tumors.
What ELICIO THERAPEUTICS INC does
Elicio Therapeutics is a clinical-stage biotechnology company developing lymph node-targeted cancer immunotherapies using its proprietary Amphiphile (AMP) technology platform. The company's lead program, ELI-002 7P, is a seven-peptide cancer immunotherapy currently in Phase 2 trials targeting mutant KRAS-positive pancreatic ductal adenocarcinoma and other solid tumors. The AMP technology is designed to enhance T cell responses by localizing immunotherapy payloads to lymph nodes, aiming to generate robust anti-cancer immunity without the need for personalized patient-specific manufacturing.
Themes: ["Cancer immunotherapy / checkpoint inhibitors","mKRAS-driven cancers","Pancreatic cancer (PDAC)","Colorectal cancer (CRC)","T cell therapy / T cell activation","Off-the-shelf immunotherapy"]
Fundamentals
- Price$3.49 as of 2026-07-09 close
- Market cap$82M as of 2026-07-10
- 1-year return-57.9% as of 2026-07-09 close
- Net margin-81.5% as of 2026-07-10
- Gross margin+98.5% as of 2026-07-10
- ROE-977.7% as of 2026-07-10
- Debt / equity5.75 as of 2026-07-10
- Revenue growth (YoY)-91.9% as of 2026-07-10
- Revenue CAGR (3y)-10.6% SEC XBRL
- Beta1.30 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial risk: ELI-002 7P is in Phase 2 development with no guarantee of success; the AMPLIFY-7P trial depends on achieving pre-specified disease-free survival event thresholds for final analysis","Funding and going concern: The company is unprofitable with severe revenue decline (-91.88% YoY) and depends on securing additional capital to fund ongoing clinical trials and operations","Regulatory and commercialization: Success requires FDA approval and the company must establish manufacturing and commercialization capabilities for what would be an off-the-shelf therapy competing against existing approved immunotherapies"]
Competitors & peers
- Moderna (MRNA)
- BioNTech (BNTX)
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- Regeneron (REGN)
- Jounce Therapeutics
- Tmunity Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.